ABSTRACT New evidence on breast Magnetic Resonance Imaging (MRI) screening has become available since the American Cancer Society (ACS) last issued guidelines for the early detection of breast cancer in 2003. A guideline panel has reviewed this evidence and developed new recommendations for women at different defined levels of risk. Screening MRI is recom mended for women with an approximately 20-25% or greater lifetime risk of breast cancer, including women with a strong family history of breast or ovarian cancer and women who were treated for Hodgkin disease. There are several risk subgroups for which the available data are insufficient to recommend for or against screening, including women with a personal history of breast cancer, carcinoma in situ, atypical hyperplasia, and extremely dense breasts on mam mography. Diagnostic uses of MRI were not considered to be within the scope of this review. (CA Cancer J Clin 2007;57:75-89.) © American Cancer Society, Inc., 2007. To e a rn fre e C M E c r e d it fo r s u c c e s s fu lly c o m p le tin g th e o n lin e q u iz b a s e d on th is a rtic le , g o to http://C M E .A m C ancerS oc.org.
INTRODUCTION
M ammography has been proven to detect breast cancer at an early stage and, when followed up with appropriate diagnosis and treatment, to reduce mortality from breast cancer. For women at increased risk o f breast cancer, other screening technologies also may contribute to the earlier detection o f breast cancer, particu larly in women under the age of 40 years for w hom mammography is less sensitive. The American Cancer Society (ACS) guideline for the early detection o f breast can cer, last updated in 2003, stated that women at increased risk o f breast cancer might benefit from additional screening strategies beyond those offered to women at aver age risk, such as earlier initiation o f screening, shorter screening intervals, or the addition o f screening modalities (such as breast ultrasound or magnetic resonance imaging [MRI] ) other than mammography and physical examination. However, the evidence available at the time was insufficient to justify recommendations for any of these screening approaches. The ACS recommended that decisions about screen ing options for women at significantly increased risk of breast cancer be based on shared decision making after a review o f potential benefits, limitations, and harms of different screening strategies and the degree o f uncertainty about each. 1 Although there still are limitations in the available evidence, additional pub lished studies have become available since the last update, particularly regarding Dr. Saslow is D ire c to r, B re a st and G y n e c o lo g ic C ancer, C a n ce r C o n tro l S cie nce D epartm ent, A m erica n Cancer S o cie ty, A tla n ta , GA.
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BACKGROUND

MRI
M RI utilizes magnetic fields to produce detailed cross-sectional images o f tissue structures, pro viding very good soft tissue contrast. Contrast between tissues in the breast (fat, glandular tis sue, lesions, etc.) depends on the mobility and magnetic environment of the hydrogen atoms in water and fat that contribute to the measured signal that determines the brightness of tissues in the image. In the breast, this results in images showing predominantly parenchyma and fat, and lesions, if they are present. A paramagnetic small molecular gadolinium-based contrast agent is injected intravenously to provide reliable detec tion o f cancers and other lesions. Thus, contrast enhanced M R I has been shown to have a high sensitivity for detecting breast cancer in high risk asymptomatic and symptomatic wom en, although reports of specificity have been more variable.2-8 This high signal from enhancing lesions can be difficult to separate from fat, lead ing to the use o f su b tractio n im ages or fat suppression, or both, to assess disease. Because parenchymal tissue also enhances, but generally m ore slowly than malignant lesions, and also because contrast can wash out rapidly from some tumors, it is important to look at images at an early time point after contrast injection (typically 1 to 3 minutes). M R I examinations may involve examining images at one time point or, more often, will collect a preinjection image with sequential sets of images after contrast injection (dynamic contrast-enhanced [DCE]-MRI). Both the appearance o f lesions and, where available, the uptake and washout pattern can be used to identify malignant disease and discriminate it from benign conditions. These techniques, which have been widely employed for assessing symptomatic disease, have recently been shown to provide good sensitiv ity as a screening tool for breast cancer in women at increased risk based on family history.9-14 The approach requires appropriate techniques and equipm ent, together w ith experienced staff. H igher quality images are produced by dedi cated breast M R I coils, rather than body, chest, or abdominal coils.
IDENTIFICATION OF WOMEN WITH A HIGH RISK OF BREAST CANCER
Three approaches are available for identify ing women with a high risk o f breast cancer: family history assessment, genetic testing, and review of clinical history. All contribute to iden tifying wom en who are candidates for breast M R I screening.
Family History
Although a high proportion of women in the general population have at least one relative with breast cancer, for the majority o f these women, this "family history" either does not increase risk at all (ie, the cancer was sporadic) or is associ ated with, at most, a doubling of lifetime risk (due to either shared environmental risk factors or an inherited gene o f low penetrance). Only 1% to 2% o f women have a family history sug gestive of the inheritance of an autosomal dom inant, high-penetrance gene conferring up to an 80% lifetime risk o f breast cancer. In some families, there is also a high risk o f ovarian cancer. Features of the family history which suggest the cancers may be due to such a highpenetrance gene include 2 or more close (gen erally first-or second-degree) relatives with breast or ovarian cancer; breast cancer occurring before age 50 years (premenopausal) in a close relative; a family history o f both breast and ovarian can cer; one or more relatives with 2 cancers (breast and ovarian cancer or 2 independent breast can cers); and male relatives with breast cancer.15-18
Two breast/ovarian cancer susceptibility genes, BRC A1 and BRC A2, have been identified. 19, 20 Inherited mutations in these genes can be found in approximately 50% o f families in which an inherited risk is strongly suspected based on the frequency and age of onset of breast cancer cases, and in most families in which there is a much higher than expected incidence of both breast and ovarian cancer.
Several models can assist clinicians to estimate breast cancer risk or the likelihood that a BRC A m u ta tio n is present (O nline S upplem ental Material). The Gail, Claus, and 
Genetic Testing
The prevalence o f B R C A mutations is esti mated to be between 1/500 and 1/1,000 in the general population28; however, in women ofJewish ethnicity, the prevalence is 1/50.29,30 Women with cancer-predisposing mutations in either BRCA1 or B R C A 2 have an increased risk o f both breast and ovarian cancer. From population-based studies, women with BRCA1 mutations are esti mated to have a 65% risk by age 70 years for developing breast cancer (95% confidence inter val [CI], 44% to 78%); the corresponding risk for B R C A 2 mutations is 45% (95% CI, 31% to 56%).31 Risks estimated from cancer-prone fam ilies seen in referral centers are higher, with limit o f risk in the 85% to 90% range.31 These muta tions follow an autosomal dominant pattern of transmission, which means that the sister, mother, or daughter o f a woman with a B R C A m uta tion has a 50% chance of having the same muta tion.
The benefits and risks of genetic testing are beyond the scope of this article, but are reviewed in the American Society o f Clinical Oncology policy statement update on genetic testing for cancer susceptibility.32 G enetic testing for a BRCA1 or BRC A2 mutation is generally offered to adult m em bers o f families w ith a know n B R C A mutation, or to women with at least a 10% likelihood o f carrying such a m utation, based on either validated family history criteria or one o f the above-m entioned models. If a woman from a family in which a B R C A muta tion has been previously identified does not have that mutation, one can generally safely conclude that her breast cancer risk is no higher than it would have been if she did not have a family history o f breast cancer. However, in a high-risk family w ithout a know n m utation, failure to find a mutation in a particular member does not reduce her risk estimate.
A high risk o f breast cancer also occurs with mutations in the TP53 gene (Li-Fraumeni syn drom e) and the P T E N gene (C ow den and B an n ay an -R iley -R u v alcab a syndrom es).33 Accurate prevalence figures are not available, but these conditions appear to be very rare. 34, 35 Clinical Indicators of Risk Some clinical factors are associated with sub stantial breast cancer risk. Among women with Hodgkin disease, increased breast cancer risk has been consistently and significantly associated with mantle field radiation treatment. In several studies o f w om en treated betw een 1955 and 1995, risk was inversely related to age at treat ment in patients diagnosed between the ages of 10 to 30 years, with only slight or no increased risk when diagnosis was before age 10 years or after age 30 years.36-41 Risk following treatment with radiation and chemotherapy was half that o f tre a tm e n t w ith ra d ia tio n alone in tw o studies,39,42 w hich may reflect the effect of chemotherapy on earlier onset of menopause; risk was equivalent in a third study. Atypical ductal hyperplasia (ADH) is part of the continuum o f ductal proliferative breast dis eases ranging from usual ductal hyperplasia to ductal carcinoma in situ (DCIS). The literature review by Arpino et al45 suggests a 4-to 5-fold increased risk o f invasive breast cancer (com pared with a 6-to 10-fold risk with LCIS) at a median follow up of 17 years, which is doubled if the woman has an associated family history of breast cancer. It is unclear, however, what per centage of the women with this family history and ADH are at this significantly increased risk because they are carriers of a BRC A1 or 2 gene mutation.
Mammographic density has been shown to be a strong independent risk factor for the devel opment of breast cancer.48-51 In several studies, women with the most breast density were found to have a 4-to 6-fold increased risk of breast can cer, compared with women with the least dense breasts.52-56 For example, women with 75% or higher mammographic density had a more than five-fold increased risk o f breast cancer, com pared with women with less than 1% density.57 In addition, it has been shown that malignant tumors of the breast are more likely to arise in the areas of greatest mammographic density, com pared with the more fatty areas of the breast.58
The absolute risk o f contralateral breast can cer in women with a personal history o f breast cancer is estimated to be 0.5% to 1% per year, or 5% to 10% during the 10 years following diag nosis, significantly higher than that of the gen eral population.59 H o rm o n e therapy a n d /o r chem otherapy for the prim ary cancer is likely to subsequently low er the risk o f contralat eral breast cancer.
EVIDENCE AND RATIONALE
Evidence of Efficacy from MRI Screening Studies
In the mid to late 1990s, at least 6 prospective, nonrandom ized studies were initiated in The Netherlands, the United Kingdom (UK), Canada, Germany, the United States (US), and Italy to determine the benefit of adding annual M R I to (film) mammography for women at increased risk of breast cancer. Some of the studies included ultrasound and/or clinical breast examination, as well. Despite substantial differences in patient population (age, risk, etc.) and M R I technique, all reported significantly higher sensitivity for M R I compared with mammography (or any of the other modalities). All studies that included more than one round of screening reported inter val cancer rates below 10%. Participants in each of these 6 studies had either a docum ented BRC A1 or B R C A 2 mutation or a very strong family history of breast cancer. Some of the stud ies included women with a prior personal his tory of breast cancer.
Kriege et al screened 1,909 unaffected women aged 25 to 70 years with an estimated 15% or higher lifetime risk of breast cancer (19% proven to have a B R C A mutation) at 6 centers across The Netherlands.9 After a median of 3 rounds of screening, 50 breast cancers (44 invasive) were diagnosed. Eighty percent of the invasive can cers were detected by M RI, compared with 33% by mammography. However, mammography outperformed M R I for detecting DCIS. O f the invasive cancers, 43% were 1 cm or smaller in diameter, and 33% had spread to axillary lymph nodes. The specificity of M R I was 90%, com pared with 95% for mammography.
Leach et al screened 649 unaffected women aged 35 to 49 years who had at least a 25% life time risk of breast cancer (19% proven to have a BRC A mutation) at 22 centers in the UK.11 After a median o f 3 rounds o f screening, 35 cancers (29 invasive) were diagnosed. Sensitivity of M RI was 77%, compared with 40% for mammography, with specificities of 81% and 93%, respectively. M R I was most sensitive and mammography least sensitive for women with B R C A 1 mutations. Forty-five percent of the cancers were 1 cm or less in size, and 14% had spread to axillary lymph nodes. There were two interval cancers.
W arner et al screened 236 wom en aged 25 to 65 years with a B R C A mutation at a single center in Toronto for up to 3 years and detected 22 cancers (16 invasive).14 Sensitivity o f M R I was 77%, compared with 36% for mammogra phy, with 50% of the cancers 1 cm or smaller, and 13% were node positive. There was one interval cancer. Specificity was 95% for M R I and 99.8% for mammography.
Kuhl et al screened 529 women aged 30 years and older with a lifetime breast cancer risk of at least 20% at a single center in Bonn for a mean of 5 years.10 They detected 43 cancers (34 invasive), with 1 interval cancer. The sensitivity of M RI was 91%, compared with 33% for mammogra phy. The node positive rate was 16%. Specificity of both M R I and mammography was 97%.
The International Breast M R I Consortium screened 390 women aged 25 years and older with more than a 25% lifetime risk of breast can cer at 13 centers (predominantly in the US) on a single occasion.12 Four cancers were found by M R I, and only one of these by mammography. However, because the patients were not followed after screening, the false-negative rate could not be determined. M R I specificity was 95%, com pared with 98% for mammography.
In a study in Italy with 9 participating centers, Sardanelli et al screened 278 women aged 25 years and older; 27% carried a B R C A m utation or had a first-degree relative with a B R C A muta tion.13 After a median o f 1.4 rounds o f screen ing, 18 cancers (14 invasive) were found. M RI sensitivity was 94%, compared w ith 59% for mammography, 65% for ultrasound, and 50% for clinical breast examination. M R I specificity was 99%.
Overall, studies have found high sensitivity for M RI, ranging from 71% to 100% versus 16% to 40% for mammography in these high-risk populations. Three studies included ultrasound, which had sensitivity similar to mammography. The Canadian, D utch, and U K studies9,11,14 reported similar sensitivity (71% to 77%) within CIs for M R I, although the single-center study from Germany10 reported a higher sensitivity, which may reflect the concentration o f radio logical practice and higher patient volume per radiologist at a single center. There is evidence of a learning curve for radiologists conducting M RI breast screening, with the number of lesions inves tigated falling with experience.60 The three mul ticenter studies reflect the likely initial effectiveness of this modality in a population context, and it is expected that, with training and advances in technology, sensitivity will increase further. Table 2 provides a summary of these six screen ing studies.
Most of the available data are based on screen ing women at high risk due to family history and/or genetic mutations. More recently, smaller studies have provided information on the poten tial benefit o f M R I screening for women with clinical factors that put them at increased risk. Preliminary data were obtained from one retro spective study, in which Port et al61 reviewed the screening results o f 252 women with biopsyconfirmed LCIS and 126 women with atypical hyperplasia (either ductal or lobular), o f whom half were screened with annual mammography and biennial clinical exams and half were also screened w ith M R I. The w om en who were screened w ith M R I were younger and more likely to have a strong family history. M RI screen ing offered a small advantage to patients with LCIS, but not atypical hyperplasia, and also resulted in increased biopsies: 6 cancers were detected by M RI in 5 women with LCIS (4% of patients underg o in g M R I), and none were detected in women w ith atypical hyperplasia. Biopsies were recommended for 25% o f M RI screened patients; 13% of biopsies had a cancer detected. All o f the cancers in women screened with M R I were Stage 0 to I, whereas all of the cancers in women who were not screened with M R I were Stage I to II. Cancer was detected on the first M R I in 4 of 5 patients. The sensi tivity of M R I was 75%, the specificity was 92%, and the positive predictive value was 13%.
Technological Limitations and Potential Harms Associated with MRI Screening
A lthough the efficacy o f breast M R I has been demonstrated, it does not achieve perfect
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CA A Cancer Journal for Clinicians sensitivity or specificity in wom en undergo ing screening, and as such, the issue o f adverse consequences for wom en who do, but espe cially those who do not, have breast cancer is im portant to address. As w ith mammography and other screening tests, false negatives after M R I screening can be attributed to inherent technological limitations of M R I, patient char acteristics, quality assurance failures, and human error; false positives also can be attributed to these factors, as well as heightened m edicallegal concerns over the consequence o f missed cancers. A patient's desire for definitive find ings in the presence of a low-suspicion lesion may also contribute to a higher rate o f benign biopsies. The consequences o f all these fac tors include missed cancers, w ith potentially worse prognosis, as well as anxiety and poten tial harm s associated w ith interventions for benign lesions. The specificity of M R I is significantly lower than that o f mammography in all studies to date, resulting in more recalls and biopsies. Call-back rates for additional imaging ranged from 8% to 17% in the M R I screening studies, and biopsy rates ranged from 3% to 15%.9-14 However, sev eral researchers have reported that recall rates decreased in subsequent rounds o f screening: prevalence screens had the highest false-positive rates, which subsequently dropped to less than 10%.9,62,63 Most call backs can be resolved with out biopsy. The call-back and biopsy rates of M RI are higher than for mammography in high risk populations; while the increased sensitivity of M R I leads to a higher call-back rate, it also leads to a higher num ber of cancers detected. The proportion of biopsies that are cancerous (positive predictive value) is 20% to 40%.9-14 Since false-positive results appear to be common, more data are needed on factors associated with lower specificity rates. Table 3 compares the likelihood of detection and follow-up tests for women who underwent screening M R I and m am m ography in two screening studies (Dutch and UK). The study populations differed, with the Dutch study hav ing a wider age group and lower risk category, compared with the UK study.9,11 This affected both the prevalence of cancer and the pick-up rate by modality in the two studies. These results, drawn from two trials, demonstrate the rela tively high recall rate in the high-risk popula tion, as well as the fact that M R I is a relatively new technique. Despite the high num ber of recalls, because of the high cancer rate, the rate of benign surgical biopsy in the UK study per cancer detected was similar to that experienced in the population-based national breast screen ing service. Recalls will inevitably lead to addi tional investigations, many of which will not demonstrate that cancer is present.
Given the high rate of cancer combined with the risk of false-positive scans in a high-risk pop ulation undergoing M RI-based screening, the psychological health of these w om en m erits study. In a subgroup o f 611 women in the UK study, 89% reported that they definitely intended to return for further screening, and only 1% def initely intended not to return. However, 4% found breast M R I "extremely distressing," and 47% reported still having intrusive thoughts about the examination 6 weeks afterward.64
In a sample o f 357 women from the Dutch study, psychological distress remained within norm al lim its th roughout screening for the group as a whole. However, elevated breast cancer-specific distress related to screening was found in excessive (at least once per week) breast self-examiners, risk overestimators, and women closely involved in the breast cancer case of a sis ter. At least 35% of the total sample belonged to one of these subgroups. It was recommended that patients in one o f these vulnerable sub groups be approached for additional psycho logical support.65
In a small sample of women from the Toronto study followed over a course o f 2 years, there was no evidence o f any effect on global anxiety, depression, or breast cancer-related anxiety.66 In another sample of 57 women, almost 50% had elevated baseline general and/or breast cancerspecific anxiety, but in 77% o f cases this was attributed by the patients to life events, includ ing relatives with cancer. A nonsignificant increase in general anxiety and breast cancer-related anx iety, compared with baseline, was found in the subset of women recalled for further imaging or biopsies.67 Follow-up time is still insufficient to determine whether anxiety scores return to base line once the work up has been completed.
T here is a special responsibility to alert patients to this technology, w ith its potential strengths and harms, and to be encouraging, while allowing for shared decision making. The interplay betw een risks, benefits, limitations, and harms is complicated by the fact that indi vidual wom en likely will weigh these differ ently depending on their age, values, perception of risk, and their understanding of the issues. Steps should be taken to reduce anxiety asso ciated with screening and the waiting time to diagnosis, and conscientious efforts should be made to inform women about the likelihood o f both false-negative and false-positive find ings. How information is conveyed to the patient greatly influences the patient's response: it is im portant that providers not convey an undue sense of anxiety about a positive M R I finding. W hile the high rate o f biopsies and further investigations is acceptable in wom en w ith a high risk of breast cancer, the num ber of such investigations in wom en at lower risk will be much higher than would be appropriate, lead ing to the need to counsel w om en in lower risk categories that M R I screening is not advis able and that the harms are believed to out weigh the benefits. Such advice needs to be based on considerations of family history, genetic m utation status, other risk factors, age, and mammographic breast density.
There are substantial concerns about costs of and limited access to high-quality M R I breast screening services for women with familial risk. In addition, MRI-guided biopsies are not widely available. W ith many communities not provid ing M R I screening and with M RI-guided biop sies not widely available, it is recognized that these recommendations may generate concerns in high-risk women who may have limited access to this technology.
The ability of M R I to detect breast cancer (both invasive and in situ disease) is directly related to high-quality imaging, particularly the signalto-noise ratio, as well as spatial resolution o f the M R image. In order to detect early breast can cer (ie, small invasive cancers, as well as DCIS), simultaneous imaging of both breasts with high spatial resolution is favored. High spatial resolu tion imaging should be performed with a breast coil on a high field magnet with thin slices and high matrix (approximately 1 mm in-plane res olution). These technical parameters are consid ered to be the minimal requirements to perform an adequate breast M RI study. The ability to per form M RI-guided biopsy is absolutely essential to offering screening M RI, as many cancers (par ticularly early cancers) will be identified only on M R I. T he A m erican College o f R adiology (ACR) is currently developing an accreditation process for performing breast M RI, and, in addi tion to the performance of high spatial resolu tio n im ages, th e a b ility to p e rfo rm M R I intervention (ie, needle localization and/or biopsy) will be essential in order to obtain accreditation by this group. Accreditation will be voluntary and not mandatory. This guideline will likely be available in 2007.
There is a learning curve with respect to inter pretation for radiologists. Published trial sites that experience a high volume of cases are expe rienced, but community practice groups have reported call-back rates over 50% in the major ity o f the studies that are interpreted. Experience and familiarity with patterns of enhancement, normal and possibly abnormal, are thought to decrease recall rates and increase positive biopsy rates. The A C R accreditation process will stip ulate a minimum number o f exams that must be read for training purposes and a minimum num ber for ongoing accreditation. Sites performing breast M R I are encouraged to audit their call back rates, biopsy rates, and positive biopsy rates.
Cost-effectiveness
Only limited data are available on the costeffectiveness of breast M RI screening. One recent study modeled cost-effectiveness for adding M RI to mammography screening for women of dif ferent age groups w ho carry a B R C A 1 or BRC A2 mutation.68 The authors concluded that the cost per quality-adjusted life year (QALY) saved for annual M R I plus film mammography, compared with annual film mammography alone, varied by age and was more favorable in carri ers o f a m u tatio n in B R C A 1 than B R C A 2 because BRC A 1 mutations confer higher can cer risk, and higher risk of more aggressive can cers, than B R C A 2 mutations.31 Estimated cost per QALY for women aged 35 to 54 years was $55,420 for women with a B R C A 1 mutation and $130,695 for women with a BRC A 2 muta tion. Cost-effectiveness was increased when the sensitivity of mammography was lower, such as in women with very dense breasts on mammog raphy: estimated costs per QALY were $41,183 for women with a BRCA1 mutation and $98,454 for women with a BR_CA2 mutation with dense breast tissue. The most important determinants o f cost-effectiveness were breast cancer risk, mammography sensitivity, M R I cost, and qual ity of life gains from M RI.
An evaluation of the cost-effectiveness o f the UK study69 has determined that the incremen tal cost per cancer detected for women at approx im ately 50% risk o f carrying a B R C A gene mutation was $50,911 for M R I combined with mammography over mammography alone. For known mutation carriers, the incremental cost per cancer detected decreased to $27,544 for M R I combined with mammography, compared with mammography alone. Analysis supporting the introduction of targeted M R I screening in the U K for high-risk wom en70 identified the increm ental cost of com bined screening per QALY in 40-to 49-year-old women as $14,005 for a BRC A1 carrier with a 31% 10-year riskthe group in which M R I screening is seen to be most effective; $53,320 for wom en with a 12% 10-year risk; and $96,379 for women with a 6% 10-year risk. For the 30-to 39-year-old age range, the incremental costs per QALY are $24,275 for a B R C A 1 carrier w ith an 11% 10-year risk and $70,054 for a women with a 5% 10-year risk. Based on these estimates, which are based on costs within the UK National Health Service, M RI screening will be offered to women at familial risk aged 30 to 39 years at a 10-year risk greater than 8%, and to women at familial risk aged 40 to 49 years at a 10-year risk greater than 20%, or greater than 12% when mammog raphy has shown a dense breast pattern.
Evidence Supporting Benefit of MRI Screening Among Women in Different Risk Categories
The guideline recommendations were based on consideration of (1) estimates of level of risk for women in various categories and (2) the extent to which risk groups have been included in M RI studies, or to which subgroup-specific evidence is available. Because of the high false-positive rate of M RI screening, and because women at higher risk of breast cancer are much more likely to ben efit than women at lower risk, screening should be recommended only to women who have a high prior probability of breast cancer. There is growing evidence that breast cancer in women with specific mutations may have biological and histological features that differ from sporadic can cers. This may result in observed variations in the sensitivity of M R I relative to mammogra phy in detecting cancer in women with a BRCA mutation and those at high familial risk, but with out mutations in these genes.11
Women at Increased Risk Based on Family History
The threshold for defining a woman as hav ing significantly elevated risk o f breast cancer is based on expert opinion. Any woman with a BR_CA1 or BR_CA2 mutation should be con sidered at high risk. The panel has not restricted its recommendations only to women with BRCA mutations because B R C A testing is not always available or informative, and other risk indica tors identify additional subsets of women with increased breast cancer risk. If mutation testing is not available, has been done and is noninfor mative, or if a woman chooses not to undergo testing, pedigree characteristics suggesting high risk may be considered. Very careful family his tory analysis is required, using tools such as BRCAPRO.18,26 Risk assessment is likely to offer the greatest potential benefit for women under the age of 40 years. Table 4 provides examples of women with a family history indicative of mod erate and high risk. The online supplemental material provides guidance for accessing and using risk assessment models.
American Cancer Society Guidelines fo r Breast Screening with M R I as an A djunct to Mammography
Women at Increased Risk Based on Clinical Factors
Additional factors that increase the risk of breast cancer, and thus may warrant earlier or more fre quent screening, include previous treatment with chest irradiation (eg, for Hodgkin disease), a per sonal history of LCIS or ADH, mammographically dense breasts, and a personal history of breast cancer, as discussed above. There are little data to assess the benefit o f M R I screening in women with these risk factors. Women at increased risk or who are concerned about their risk may find it helpful to have their provider clarify the bases for M R I screening recommendations, as well as areas of uncertainty. For some women, mammog raphy may be as effective as for women at average risk, and M R I screening may have little added benefit. In contrast, mammography is less effec tive in women with very dense breasts, and M RI screening may offer added benefit.
W omen who have received radiation treat ment to the chest, such as for Hodgkin disease, compose a well-defined group that is at high risk. Although evidence of the efficacy of M RI screen ing in this group is lacking, it is expected that M R I screening might offer similar benefit as for women with a strong family history, particularly at younger ages and within 30 years of treatment. Because of the high risk o f secondary breast can cer in this group, M RI screening is recommended based on expert consensus opinion.
While lifetime risk of breast cancer for women diagnosed with LCIS may exceed 20%, the risk o f invasive breast cancer is continuous and only moderate for risk in the 12 years following local excision.46 Only one M R I screening study has included a select group o f women with LCIS,61
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CA A Cancer Journal for Clinicians which showed a small benefit over mammogra phy alone in detecting cancer. This benefit was not seen in patients with atypical hyperplasia. M R I use should be decided on a case-by-case basis, based on factors such as age, family his tory, characteristics o f the biopsy sample, breast density, and patient preference.
A lth o u g h th ere have b e e n several trials reported looking at the accuracy and positive predictive value o f M R I and mammography in women with high breast density, all o f these tri als have been conducted in women with known or highly-suspected malignancies w ithin the breast.71-74 To this point, there has been no Phase III randomized trial reported that has shown a reduction in either mortality or in the size of diagnosed breast cancer when comparing breast M R I with mammography in women with high mammographic density.
Scant data are available for M R I screening of women with a personal history of breast cancer. In one study, M R I detected more cancers in women who had both a personal history and a family history, compared with women at high risk based on family history alone.75 While women with a previous diagnosis o f breast cancer are at increased risk o f a second diagnosis, the ACS panel concluded that the estimated absolute life time risk of 10% does not justify a recommenda tion for M R I screening at the present time.
Limitations of Evidence from MRI Studies and Research Needs
Assiduous attempts were made to base rec ommendations on solid evidence. However, out come data from screening M R I studies are not sufficient to form a solid basis for many of the rec ommendations. It was therefore necessary to rely on available inferential evidence and expert opin ion to provide the guidance needed for patients and their health care providers.
Although the literature shows very good evi dence for greater sensitivity of M R I than mam mography and good evidence for a stage shift toward earlier, more favorable tum or stages by M R I in defined groups of women at increased risk, there are still no data on recurrence or survival rates, and therefore, lead-time bias is still a concern. Further, a large randomized, mor tality endpoint study is unlikely to take place, and it will be necessary in the foreseeable future to rely on evidence o f stage o f disease and types of cancers. In the absence o f randomized trials, recurrence and survival data will come from observational study designs.
The age at which screening should be initi ated for women at high risk is not well estab lished. The argument for early screening is based on the cumulative risk of breast cancer in women with BRCA1 mutations and a strong family his tory o f early breast cancer, which is estimated to be 3% by age 30 years and 19% by age 40 years.76 Population-based data also indicate that risk for early breast cancer is increased by a family history of early breast cancer.16 Based on these observations, some experts have suggested that breast cancer screening begin 5 to 10 years before the earliest previous breast cancer in the family. In 1997, an expert panel suggested that screening be initiated at some time between the ages o f 25 and 35 years for w om en w ith a BRC A1 or B R C A 2 m utation.77 Because these recommendations were based on limited obser vational data, the decision regarding w hen to initiate screening should be based on shared deci sion making, taking into consideration individ ual circumstances and preferences. N o data are available related to the effectiveness of screening w om en beyond age 69 years w ith M R I and m am m ography versus m am m ography alone; most of the current data are based on screening in younger women, and thus, similar investiga tions are needed in older age cohorts. For most women at high risk, screening with M R I and mammography should begin at age 30 years and continue for as long as a woman is in good health. 1 Most of the available data are based on annual M RI screening; there is a lack of evidence regard ing shorter or longer screening intervals. Further, while good data are available for the first screen ing exam (ie, the "prevalent screen"), consider ably less data are available from subsequent screening exams (ie, "incidence screens"), and the available data include relatively short followup times. Most studies of annual M RI have shown few interval cancers, certainly fewer than with mammography. Given the probably shorter dura tion of the detectable preclinical phase, or sojourn time, in women with B R C A mutations, M R I has demonstrated superiority to mammography Volume 57 • Number 2 • March/April 2007 in this regard. Therefore, to the best of our knowl edge, M R I should be perfo rm ed annually. However, in view of data suggesting that tumor doubling time in women with an inherited risk decreases with age,78 it is conceivable that older women can safely be screened less frequently than younger women. The available evidence is lim ited, and additional research regarding optimal screening interval by age and risk status is needed.
Some experts recommend staggering M R I screening and mammography screening every 6 m onths. T he p o ten tia l advantage o f this approach is that it may reduce the rate o f inter val cancers. O ther experts recom m end M R I and mammography at the same time or within a short time period. This approach allows for the results o f both screening tests to be inter preted together and reported to the patient at the same time. All o f the clinical trials screened participants with both M R I and mammogra phy at the same time. There is no evidence to support one approach over the other. For the majority o f women at high risk, it is critical that M R I screening be provided in addition to, not instead of, mammography, as the sensitivity and cancer yield o f M R I and mammography com bined is greater than for M R I alone. However, where there is a concern about raised radiation sensitivity, it may be advisable to employ M RI alone despite the overall lower sensitivity.
In order to pursue answers to some o f the unresolved questions related to the use of M RI and mammography to screen women at increased risk, it is important to develop creative strategies related to data g athering and study design. Multicenter studies can result in greater efficiency in accumulating sufficiently large enough data sets in this subgroup of women. Conventional study designs with randomization may prove dif ficult given the potential advantage o f adding M R I to mammography in higher-risk groups, and thus, design strategies that utilize surrogate markers and historic controls may prove both more practical and feasible. To move forward, we encourage the development of a simple, com m on data collection protocol to capture infor mation from the growing number of centers that offer M R I and formal systems to collect out come data. Because many insurers presently cover M R I screening for high-risk women, it may be economical to do prospective surveillance stud ies since screening costs are covered by third par ties. A com m on surveillance protocol could perm it pooling o f data, m uch like presently is done w ithin the fram ew ork o f the N ational Cancer Institute's Breast Cancer Surveillance Consortium, a collaborative network o f seven mammography registries in the U nited States with linkages to tum or and/or pathology reg istries that was organized to study the delivery and quality o f breast cancer screening and related patient outcomes in the United States.79 We also encourage seeking opportunities for broad inter national research collaboration on study ques tions o f comm on interest.
Several further clinical trials of screening women at increased risk o f breast cancer are underway, including an international study o f M R I and ultrasound in conjunction with the International Breast M R I Consortium and Cancer Genetics Network, and the American College of Radiology Imaging Network (ACRIN) 666 screening trial o f mammography compared with ultrasound. An amendment to the A C R IN trial, 6666, will screen patients with one round of M RI.
CONCLUSION
O ften no available screening m odality is uniquely ideal. For breast M RI, there is an increas ing body of observational data showing that screen ing can identify cancer in patients of specific risk groups, ie, high-risk patients facing a lifetime risk of~20-25% or greater related to family history as estimated by one or more o f the different risk models. We have specified a range of risk because estimates from the risk models vary and because each of the risk models is imperfect. Furthermore, these models likely will continue to be refined over time; therefore, these risk estimates for dif ferent family history profiles are likely to change. Thus, when estimating patient risk it is impor tant to always be certain that the most current model is being used. In addition to family his tory, clinical factors as described earlier may be a relevant factor in individualized decisions about M RI screening when family history alone does not predict a risk of approximately 20-25%.
Several studies have demonstrated the ability o f M R I screening to detect cancer with early-
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stage tumors that are associated with better out comes. While survival or mortality data are not available, M R I has higher sensitivity and finds smaller tumors, compared with mammography, and the types o f cancers found with M R I are the types that contribute to reduced mortality. It is reasonable to extrapolate that detection of noninvasive (DCIS) and small invasive cancers will lead to mortality benefit.
The guideline recom m endations for M R I screening as an adjunct to mammography for women at increased risk o f breast cancer take into account the available evidence on efficacy and effectiveness o f M R I screening, estimates of level o f risk for women in various categories based on both family history and clinical fac tors, and expert consensus opinion where evi dence for certain risk groups is lacking. All of these groups of women should be offered clin ical trials of M R I screening, if available. Women should be informed about the benefits, limita tions, and potential harms o f M R I screening, including the likelihood o f false-positive find ings. Recommendations are conditional on an acceptable level o f quality of M R I screening, w hich should be perform ed by experienced providers in facilities that provide M RI-guided biopsy for the follow up of any suspicious results.
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